Combining traditional dermatopathology with PCR-based molecular testing improves diagnostic accuracy in differentiating ...
Oral cancer remains one of the deadliest cancers worldwide, with survival rates that have shown frustratingly little ...
Q4 2025 Management View CEO Joshua Riggs announced the submission of GraftAssureDx to the FDA, emphasizing, “we are, to our knowledge, the first dd-cfDNA assay to be submitted to the FDA for ...
IMDX is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of IMDX shares has decreased $0.10 since the market last closed. This is a 1.74% ...
Submitted GraftAssureDx™ for kidney transplant rejection testing for FDA review on Wednesday, March 25Welcomed second ...
The development aligns with recent guidance from the WHO concerning tuberculosis molecular diagnostics in India.
In the following sections, we highlight ethical concerns about early adoption of molecular diagnostic testing without solid evidence or guidelines and offer practical guidance for ethical ...
Castle Biosciences reported strong Q4/FY2025 revenue growth and robust cash reserves but faces a projected EPS decline in ...
Plus Therapeutics, Inc. (Nasdaq: PSTV) ('Plus” or the 'Company”), a healthcare company developing and commercializing ...
When Domain Associates led Xagenic Inc.’s recent $20 million Series B, it marked the eighth diagnostics investment the firm had made with its $500 million eighth fund. The partners say they’ve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results